688076.SH
ST诺泰
SSE · Healthcare · Biotechnology · CN
CNY 27.14
−0.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.9B | 1.9B | 1.6B | 1.0B | 651.3M |
| Cost of Revenue | 767.6M | 725.8M | 525.1M | 403.4M | 276.3M |
| Gross Profit | 1.2B | 1.2B | 1.1B | 630.2M | 375.0M |
| Operating Expenses | |||||
| R&D Expense | 226.6M | 251.9M | 227.4M | 124.9M | 69.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 308.1M | 334.4M | 290.7M | 222.6M | 158.0M |
| Selling & Marketing Expense | 94.7M | 98.1M | 62.0M | 57.6M | 35.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 714.6M | 753.9M | 607.8M | 423.9M | 271.5M |
| Cost and Expenses | 1.5B | 1.5B | 1.1B | 827.3M | 547.8M |
| Operating Income (EBIT) | 381.5M | 408.6M | 448.2M | 189.7M | 123.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 333.6M | 360.5M | 438.5M | 173.1M | 121.9M |
| Income Tax Expense | 29.2M | 35.1M | 38.7M | 7.7M | 200.2K |
| Bottom Line | |||||
| Net Income | 309.3M | 332.4M | 404.4M | 162.9M | 128.0M |
| Earnings from Cont. Ops | 304.4M | 325.4M | 399.8M | 165.5M | 121.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 309.3M | 332.4M | 404.4M | 162.9M | 128.0M |
| Per Share | |||||
| Basic EPS | CN¥0.98 | CN¥1.06 | CN¥1.34 | CN¥0.76 | CN¥0.60 |
| Diluted EPS | CN¥0.98 | CN¥1.06 | CN¥1.31 | CN¥0.76 | CN¥0.60 |
| Revenue Per Share | CN¥6.11 | CN¥6.20 | CN¥5.38 | CN¥4.82 | CN¥3.05 |
| Shares | |||||
| Basic Shares Outstanding | 315.8M | 313.6M | 301.8M | 214.4M | 213.4M |
| Diluted Shares Outstanding | 315.8M | 313.6M | 301.8M | 214.4M | 213.4M |
| Profitability Metrics | |||||
| EBITDA | — | 722.4M | 657.8M | 326.0M | 227.1M |
| D&A | — | 313.8M | 209.6M | 136.4M | 103.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026